Business
SCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022
JERSEY CITY, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and
About this update from Scynexis, Inc.
[{"type":"text","content":"JERSEY CITY, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will present posters at four upcoming U.S. and international medical conferences in September. United States Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting – September 7-9, 2022, Albuquerque, N.M.Title: Outcomes of Oral Ibrexafungerp in Refractory Patients with Candida Infections from an Open-Label Study in Patients with Serious Fungal Infections (FURI)Date: Friday, September 9Time: 3:30 pm – 5:00 pm MDTPresenter: Nkechi Azie, M.D.Title: Outcomes of Oral Ibrexafungerp in the Treatment of 10 Patients with Candida auris Infections, from the CARES StudyDate: Friday, September 9Time: 3:30 pm – 5:00 pm MDTPresenter: Nkechi Azie, M.D. World Anti-Microbial Resistance (AMR) Congress – September 7-9, 2022, National Harbor, Md.Title: Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of CDC Urgent Threat Pathogen, Candida aurisDate: Wednesday, September 7, and Thursday, September 8Time: 10:20 am EDT both daysPresenter: Thomas King, MS, MPH International International Immunocompromised Host Society (ICHS) – September 8-11, 2022, Basel, SwitzerlandTitle: Oral Ibrexafungerp Outcomes in Patients with Chronic Mucocutaneous Candidiasis (CMC)Date: Saturday, September 10Time: 10:00 am -10:30 am CESTPresenters: Riina Rautemma-Richardson and Chris Eades, Manchester University 21st Congress of the International Society for Human and Animal Mycology (ISHAM) –September 20-24, 2022, New Delhi, IndiaTitle: All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Open-label Study (FURI)Date: Wednesday, September 21Time: 12:30 pm - 1:30 pm ISTPresenter: Juergen Prattes, M.D., Medical University of GrazTitle: Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)Date: Wednesday, September 21Time: 12:30 pm - 1:30 pm ISTPresenter: Juergen Prattes, M.D., Medical University of Graz About SCYNEXISSCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to...